Search This Blog

Tuesday, May 19, 2026

UBS upgrades Jazz Pharmaceuticals to Buy from Neutral, raises price target

 

UBS upgrades Jazz Pharmaceuticals to Buy from Neutral, raises price target to $307 on base business, Ziihera outlook

  • UBS cites improved confidence in the company’s base business as a key driver of the upgrade
  • UBS highlights Ziihera’s commercial potential in its reasoning for the Buy rating and higher target
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)